Erythroid Progenitor Cell Line for Hematological Disease Applications
Posted May 04 2010 5:00pm
Description of Invention: Plasmodium vivax (malaria) is a significant health concern in many parts of Asia, Latin America, North Africa, and the Middle East. There is a lack of continuous culture systems for this pathogen. The subject technology is an erythroid progenitor continuous cell line (termed CD36E) identified by erythroid markers CD36, CD33, CD44, CD71, CD235, and globoside. These CD36E cells are heterozygous for Fya and Fyb (Duffy antigen). Due to recent evidence that Plasmodium vivax (P. vivax) can infect erythroid progenitor cells (reference: YX Ru et al. and T Panichakul et al.), these cells can be potentially used for culturing P. vivax and other species of malaria. This in turn could aid development of malaria related treatments and/or products. In addition, the cell line can also be used for other hematological disease applications that involve red blood cells or red blood cell precursors. The CD36E cells also produce alpha, beta, and chi hemoglobin and therefore may be used for research involving hemoglobin.
Culture system for Plasmodium species (malaria)
Advantages: Immortalized erythroid progenitor cell line
Development Status: In vitro data can be provided upon request.
Inventors: Susan Wong (NHLBI) Ning Zhi (NHLBI) Neal S Young (NHLBI)
Patent Status: HHS, Reference No. E-151-2010/0
Research Tool -- patent protection is not being pursued for this technology
YX Ru et al. Invasion of erythroblasts by Pasmodium vivax: A new mechanism contributing to malarial anemia. Ultrastruct Pathol. 2009 Oct;33(5):236-242. [ PubMed: 19895296 ]
T Panichakul et al. Production of erythropoietic cells in vitro for continuous culture of Plasmodium vivax. Int J Parasitol. 2007 Dec;37(14):1551-1557. [ PubMed: 17610880 ]
Licensing Status: Available for biological materials licensing.
Collaborative Research Opportunity: The National Heart Lung and Blood Institute, Hematology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the CD36E cell line. Please contact Cecilia Pazman, Ph.D., at email@example.com for more information.
Portfolios: Infectious Diseases Infectious Diseases - Research Materials
For Additional Information Please Contact: Kevin Chang Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-5018 Fax: 301-402-0220